What is Emergent Biosolutions Inc's earnings per share (EPS)?

Emergent Biosolutions Inc (EBS) reported diluted earnings per share of $0.93 for fiscal year 2025. This represents a 125.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Emergent Biosolutions Inc Financials

EBS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Emergent Biosolutions Inc (EBS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 57/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Emergent Biosolutions Inc has an operating margin of 13.5%, meaning the company retains $13 of operating profit per $100 of revenue. This results in a moderate score of 52/100, indicating healthy but not exceptional operating efficiency. This is up from -10.4% the prior year.

Growth

Emergent Biosolutions Inc's revenue declined 28.8% year-over-year, from $1.0B to $742.9M. This contraction results in a growth score of 0/100.

Leverage

Emergent Biosolutions Inc carries a low D/E ratio of 1.09, meaning only $1.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 80/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.01, Emergent Biosolutions Inc holds $5.01 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Emergent Biosolutions Inc converts 21.1% of revenue into free cash flow ($156.8M). This strong cash generation earns a score of 78/100.

Returns

Emergent Biosolutions Inc's ROE of 10.1% shows moderate profitability relative to equity, earning a score of 33/100. This is up from -39.5% the prior year.

Altman Z-Score Distress

1.45

Emergent Biosolutions Inc scores 1.45, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Strong

8/9

Emergent Biosolutions Inc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

3.24x

For every $1 of reported earnings, Emergent Biosolutions Inc generates $3.24 in operating cash flow ($170.6M OCF vs $52.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

1.7x

Emergent Biosolutions Inc earns $1.7 in operating income for every $1 of interest expense ($100.1M vs $59.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$742.9M

YoY-28.8%

5Y CAGR-14.0%

10Y CAGR+3.6%

Emergent Biosolutions Inc generated $742.9M in revenue in fiscal year 2025. This represents a decrease of 28.8% from the prior year.

EBITDA

$195.9M

YoY+195800.0%

5Y CAGR-16.7%

10Y CAGR+1.7%

Emergent Biosolutions Inc's EBITDA was $195.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 195800.0% from the prior year.

Net Income

$52.6M

YoY+127.6%

5Y CAGR-29.7%

10Y CAGR-1.8%

Emergent Biosolutions Inc reported $52.6M in net income in fiscal year 2025. This represents an increase of 127.6% from the prior year.

EPS (Diluted)

$0.93

YoY+125.8%

5Y CAGR-30.4%

10Y CAGR-4.1%

Emergent Biosolutions Inc earned $0.93 per diluted share (EPS) in fiscal year 2025. This represents an increase of 125.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$156.8M

YoY+338.0%

5Y CAGR-16.9%

Emergent Biosolutions Inc generated $156.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 338.0% from the prior year.

Cash & Debt

$205.4M

YoY+106.4%

5Y CAGR-19.9%

10Y CAGR-4.1%

Emergent Biosolutions Inc held $205.4M in cash against $572.1M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

52M

YoY-4.1%

5Y CAGR-0.5%

10Y CAGR+2.8%

Emergent Biosolutions Inc had 52M shares outstanding in fiscal year 2025. This represents a decrease of 4.1% from the prior year.

Margins & Returns

Gross Margin

56.1%

YoY+21.4pp

5Y CAGR-2.6pp

10Y CAGR-23.4pp

Emergent Biosolutions Inc's gross margin was 56.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 21.4 percentage points from the prior year.

Operating Margin

13.5%

YoY+23.9pp

5Y CAGR-14.3pp

10Y CAGR-13.6pp

Emergent Biosolutions Inc's operating margin was 13.5% in fiscal year 2025, reflecting core business profitability. This is up 23.9 percentage points from the prior year.

Net Margin

7.1%

YoY+25.3pp

5Y CAGR-12.3pp

10Y CAGR-5.0pp

Emergent Biosolutions Inc's net profit margin was 7.1% in fiscal year 2025, showing the share of revenue converted to profit. This is up 25.3 percentage points from the prior year.

Return on Equity

10.1%

YoY+49.5pp

5Y CAGR-11.0pp

10Y CAGR+0.5pp

Emergent Biosolutions Inc's ROE was 10.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 49.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$53.2M

YoY-24.8%

5Y CAGR-25.9%

10Y CAGR-7.7%

Emergent Biosolutions Inc invested $53.2M in research and development in fiscal year 2025. This represents a decrease of 24.8% from the prior year.

Share Buybacks

$24.9M

10Y CAGR+73.6%

Emergent Biosolutions Inc spent $24.9M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$13.8M

YoY-39.7%

5Y CAGR-37.3%

10Y CAGR-11.1%

Emergent Biosolutions Inc invested $13.8M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 39.7% from the prior year.

EBS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$742.9M-28.8%	$1.0B-0.5%	$1.0B-6.1%	$1.1B-37.0%	$1.8B+12.4%	$1.6B
Cost of Revenue	$326.2M-52.1%	$681.3M-3.4%	$705.4M+1.8%	$693.1M-7.4%	$748.1M+39.3%	$537.0M
Gross Profit	$416.7M+15.0%	$362.3M+14.1%	$317.6M-17.1%	$383.0M-57.0%	$891.3M-3.7%	$925.2M
R&D Expenses	$53.2M-24.8%	$70.7M-36.5%	$111.4M-40.8%	$188.3M-19.9%	$235.2M-1.1%	$237.9M
SG&A Expenses	$186.1M-39.6%	$308.0M-16.4%	$368.4M+8.5%	$339.5M-2.6%	$348.7M+14.7%	$304.1M
Operating Income	$100.1M+192.1%	-$108.7M+85.0%	-$726.4M-327.3%	-$170.0M-149.8%	$341.4M-22.1%	$438.5M
Interest Expense	$59.3M-16.5%	$71.0M-19.2%	$87.9M+135.7%	$37.3M+8.1%	$34.5M+10.2%	$31.3M
Income Tax	$30.2M-36.7%	$47.7M+62.8%	$29.3M+495.9%	-$7.4M-108.8%	$83.7M-21.1%	$106.1M
Net Income	$52.6M+127.6%	-$190.6M+74.9%	-$760.5M-259.4%	-$211.6M-196.4%	$219.5M-28.2%	$305.8M
EPS (Diluted)	$0.93+125.8%	$-3.60+75.8%	$-14.85-251.9%	$-4.22-203.9%	$4.06-28.5%	$5.68

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$148.7M-35.7%	$231.1M+64.0%	$140.9M-36.6%	$222.2M+14.1%	$194.7M-33.7%	$293.8M+15.4%	$254.7M-15.2%	$300.4M
Cost of Revenue	$84.9M-1.2%	$85.9M+28.4%	$66.9M-24.4%	$88.5M-25.0%	$118.0M-3.8%	$122.6M-58.6%	$296.1M+104.8%	$144.6M
Gross Profit	$63.8M-56.1%	$145.2M+96.2%	$74.0M-44.7%	$133.7M+32.0%	$101.3M-37.2%	$161.2M+435.8%	-$48.0M-132.5%	$147.8M
R&D Expenses	$12.1M-10.4%	$13.5M+8.0%	$12.5M-17.2%	$15.1M+65.9%	$9.1M-34.1%	$13.8M-57.8%	$32.7M+116.6%	$15.1M
SG&A Expenses	$51.1M+31.4%	$38.9M-11.0%	$43.7M-16.6%	$52.4M-13.8%	$60.8M-20.6%	$76.6M-10.8%	$85.9M+1.4%	$84.7M
Operating Income	-$27.9M-136.5%	$76.5M+4681.3%	$1.6M-96.8%	$49.9M+625.3%	-$9.5M-114.7%	$64.5M+131.7%	-$203.5M-611.3%	$39.8M
Interest Expense	$14.7M-3.3%	$15.2M+3.4%	$14.7M0.0%	$14.7M-0.7%	$14.8M+78.3%	$8.3M-64.8%	$23.6M-2.9%	$24.3M
Income Tax	$3.9M-39.1%	$6.4M+233.3%	-$4.8M-119.4%	$24.7M+567.6%	$3.7M-86.6%	$27.6M+107.5%	$13.3M+329.0%	$3.1M
Net Income	-$54.6M-206.6%	$51.2M+526.7%	-$12.0M-117.6%	$68.0M+317.3%	-$31.3M-127.3%	$114.8M+140.6%	-$283.1M-3245.6%	$9.0M
EPS (Diluted)	N/A	$0.91+513.6%	$-0.22-118.5%	$1.19	N/A	$2.06+138.3%	$-5.38-3264.7%	$0.17

EBS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.3B-5.1%	$1.4B-23.8%	$1.8B-42.4%	$3.2B+7.1%	$3.0B+2.6%	$2.9B
Current Assets	$662.5M+10.7%	$598.7M-11.9%	$679.5M-43.9%	$1.2B-4.7%	$1.3B+6.2%	$1.2B
Cash & Equivalents	$205.4M+106.4%	$99.5M-10.9%	$111.7M-82.6%	$642.6M+11.5%	$576.1M-7.3%	$621.3M
Inventory	$343.4M+10.2%	$311.7M-5.2%	$328.9M-6.2%	$350.7M+1.8%	$344.5M+12.2%	$307.0M
Accounts Receivable	$84.2M-45.5%	$154.5M-19.1%	$191.0M+20.0%	$159.2M-42.9%	$278.9M+20.8%	$230.9M
Goodwill	$0	$0	$0-100.0%	$218.2M-3.0%	$224.9M-15.7%	$266.7M
Total Liabilities	$796.0M-12.2%	$906.9M-22.7%	$1.2B-34.0%	$1.8B+32.1%	$1.3B-6.3%	$1.4B
Current Liabilities	$132.2M-18.6%	$162.4M-75.1%	$651.3M-47.0%	$1.2B+228.6%	$374.0M-2.7%	$384.5M
Long-Term Debt	$572.1M-13.8%	$663.7M+48.6%	$446.5M-0.4%	$448.5M-44.6%	$809.4M-3.8%	$841.0M
Total Equity	$522.6M+8.2%	$482.8M-25.6%	$649.3M-53.2%	$1.4B-13.9%	$1.6B+11.1%	$1.5B
Retained Earnings	-$159.8M+24.8%	-$212.4M-874.3%	-$21.8M-103.0%	$738.7M-22.3%	$950.3M+30.7%	$726.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.3B-9.7%	$1.5B+3.1%	$1.4B-0.6%	$1.4B+2.6%	$1.4B-6.0%	$1.5B-2.4%	$1.5B-16.1%	$1.8B
Current Assets	$662.5M-15.8%	$786.9M+9.4%	$719.5M+1.8%	$706.8M+18.1%	$598.7M-9.5%	$661.4M+1.1%	$654.5M-4.1%	$682.4M
Cash & Equivalents	$205.4M-16.3%	$245.5M-8.2%	$267.3M+79.3%	$149.1M+49.8%	$99.5M-33.6%	$149.9M+115.1%	$69.7M-11.2%	$78.5M
Inventory	$343.4M-3.6%	$356.3M+5.2%	$338.6M+7.8%	$314.0M+0.7%	$311.7M-3.4%	$322.7M+1.6%	$317.5M-4.8%	$333.4M
Accounts Receivable	$84.2M-43.7%	$149.5M+87.3%	$79.8M-60.8%	$203.7M+31.8%	$154.5M+27.4%	$121.3M-38.2%	$196.3M-15.9%	$233.5M
Goodwill	$0	N/A	N/A	N/A	$0	$0	$0	$0
Total Liabilities	$796.0M-9.4%	$878.5M-0.3%	$880.9M+0.9%	$873.4M-3.7%	$906.9M-6.4%	$969.4M-14.0%	$1.1B-1.1%	$1.1B
Current Liabilities	$132.2M-3.2%	$136.5M+7.4%	$127.1M+13.6%	$111.9M-31.1%	$162.4M-29.4%	$229.9M-62.9%	$619.7M-1.7%	$630.2M
Long-Term Debt	$572.1M-13.7%	$663.1M-0.7%	$667.8M+0.3%	$665.7M+0.3%	$663.7M+0.3%	$661.8M+48.1%	$447.0M+0.1%	$446.7M
Total Equity	$522.6M-10.3%	$582.5M+8.6%	$536.2M-3.0%	$552.7M+14.5%	$482.8M-5.0%	$508.4M+31.6%	$386.3M-41.8%	$663.9M
Retained Earnings	-$159.8M-51.9%	-$105.2M+32.7%	-$156.4M-8.3%	-$144.4M+32.0%	-$212.4M-17.3%	-$181.1M+38.8%	-$295.9M-2211.7%	-$12.8M

EBS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$170.6M+190.6%	$58.7M+128.5%	-$206.3M-505.0%	-$34.1M-110.6%	$320.2M-40.4%	$536.9M
Capital Expenditures	$13.8M-39.7%	$22.9M-55.6%	$51.6M-55.4%	$115.8M-48.3%	$224.1M+57.9%	$141.9M
Free Cash Flow	$156.8M+338.0%	$35.8M+113.9%	-$257.9M-72.0%	-$149.9M-256.0%	$96.1M-75.7%	$395.0M
Investing Cash Flow	$69.4M-44.6%	$125.2M-41.0%	$212.3M+155.7%	-$381.3M-70.1%	-$224.1M-47.5%	-$151.9M
Financing Cash Flow	-$136.6M+28.1%	-$190.0M+64.5%	-$535.7M-211.3%	$481.2M+441.3%	-$141.0M-302.9%	$69.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$24.9M	$0	$0-100.0%	$82.1M-22.5%	$106.0M	$0

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$77.7M+3478.3%	-$2.3M-102.2%	$106.4M+1050.0%	-$11.2M+86.0%	-$79.9M-152.0%	$153.7M+223.6%	$47.5M+175.9%	-$62.6M
Capital Expenditures	$3.9M+14.7%	$3.4M+17.2%	$2.9M-19.4%	$3.6M+111.8%	$1.7M-70.7%	$5.8M+26.1%	$4.6M-57.4%	$10.8M
Free Cash Flow	$73.8M+1394.7%	-$5.7M-105.5%	$103.5M+799.3%	-$14.8M+81.9%	-$81.6M-155.2%	$147.9M+244.8%	$42.9M+158.4%	-$73.4M
Investing Cash Flow	-$3.9M-14.7%	-$3.4M-119.8%	$17.2M-71.1%	$59.5M+108.0%	$28.6M-74.5%	$112.0M+2534.8%	-$4.6M+57.4%	-$10.8M
Financing Cash Flow	-$113.9M-616.4%	-$15.9M-148.4%	-$6.4M-1500.0%	-$400K-180.0%	$500K+100.3%	-$180.3M-254.2%	-$50.9M-225.1%	$40.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$9.1M+2.2%	$8.9M	N/A	N/A	$0	$0	N/A	N/A

EBS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	56.1%+21.4pp	34.7%+4.4pp	30.3%-4.0pp	34.3%-16.0pp	50.2%-8.4pp	58.7%
Operating Margin	13.5%+23.9pp	-10.4%+58.8pp	-69.2%-54.0pp	-15.2%-34.5pp	19.3%-8.6pp	27.8%
Net Margin	7.1%+25.3pp	-18.3%+54.2pp	-72.5%-53.5pp	-18.9%-31.3pp	12.4%-7.0pp	19.4%
Return on Equity	10.1%+49.5pp	-39.5%+77.6pp	-117.1%-101.9pp	-15.3%-28.9pp	13.6%-7.5pp	21.1%
Return on Assets	4.0%+17.7pp	-13.7%+28.0pp	-41.7%-35.0pp	-6.7%-14.1pp	7.4%-3.2pp	10.6%
Current Ratio	5.01+1.3	3.69+2.6	1.04+0.1	0.98-2.4	3.40+0.3	3.11
Debt-to-Equity	1.09-0.3	1.37+0.7	0.69+0.4	0.32-0.2	0.50-0.1	0.58
FCF Margin	21.1%+17.7pp	3.4%+28.0pp	-24.6%-11.2pp	-13.4%-18.8pp	5.4%-19.6pp	25.0%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	42.9%-19.9pp	62.8%+10.3pp	52.5%-7.7pp	60.2%+8.1pp	52.0%-2.8pp	54.9%+73.7pp	-18.9%-68.0pp	49.2%
Operating Margin	-18.8%-51.9pp	33.1%+32.0pp	1.1%-21.3pp	22.5%+27.3pp	-4.9%-26.8pp	21.9%+101.8pp	-79.9%-93.2pp	13.3%
Net Margin	-36.7%-58.9pp	22.1%+30.7pp	-8.5%-39.1pp	30.6%+46.7pp	-16.1%-55.1pp	39.1%+150.2pp	-111.1%-114.1pp	3.0%
Return on Equity	-10.4%-19.2pp	8.8%+11.0pp	-2.2%-14.5pp	12.3%+18.8pp	-6.5%-29.1pp	22.6%+95.9pp	-73.3%-74.6pp	1.4%
Return on Assets	-4.1%-7.6pp	3.5%+4.4pp	-0.9%-5.6pp	4.8%+7.0pp	-2.3%-10.0pp	7.8%+26.5pp	-18.7%-19.2pp	0.5%
Current Ratio	5.01-0.8	5.76+0.1	5.66-0.7	6.32+2.6	3.69+0.8	2.88+1.8	1.06-0.0	1.08
Debt-to-Equity	1.09-0.0	1.14-0.1	1.25+0.0	1.20-0.2	1.37+0.1	1.30+0.1	1.16+0.5	0.67
FCF Margin	49.6%+52.1pp	-2.5%-75.9pp	73.5%+80.1pp	-6.7%+35.3pp	-41.9%-92.2pp	50.3%+33.5pp	16.8%+41.3pp	-24.4%

Similar Companies

Kamada Ltd KMDA

$488.6M

Evolus EOLS

$262.2M

Siga Technologie SIGA

$375.4M

Eton Pharmaceuticals ETON

$681.8M

Canopy Growth Corp CGC

$422.8M

Frequently Asked Questions

What is Emergent Biosolutions Inc's annual revenue?

Emergent Biosolutions Inc (EBS) reported $742.9M in total revenue for fiscal year 2025. This represents a -28.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Emergent Biosolutions Inc's revenue growing?

Emergent Biosolutions Inc (EBS) revenue declined by 28.8% year-over-year, from $1.0B to $742.9M in fiscal year 2025.

Is Emergent Biosolutions Inc profitable?

Yes, Emergent Biosolutions Inc (EBS) reported a net income of $52.6M in fiscal year 2025, with a net profit margin of 7.1%.

What is Emergent Biosolutions Inc's EBITDA?

Emergent Biosolutions Inc (EBS) had EBITDA of $195.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Emergent Biosolutions Inc have?

As of fiscal year 2025, Emergent Biosolutions Inc (EBS) had $205.4M in cash and equivalents against $572.1M in long-term debt.

What is Emergent Biosolutions Inc's gross margin?

Emergent Biosolutions Inc (EBS) had a gross margin of 56.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Emergent Biosolutions Inc's operating margin?

Emergent Biosolutions Inc (EBS) had an operating margin of 13.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Emergent Biosolutions Inc's net profit margin?

Emergent Biosolutions Inc (EBS) had a net profit margin of 7.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Emergent Biosolutions Inc's return on equity (ROE)?

Emergent Biosolutions Inc (EBS) has a return on equity of 10.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Emergent Biosolutions Inc's free cash flow?

Emergent Biosolutions Inc (EBS) generated $156.8M in free cash flow during fiscal year 2025. This represents a 338.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Emergent Biosolutions Inc's operating cash flow?

Emergent Biosolutions Inc (EBS) generated $170.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Emergent Biosolutions Inc's total assets?

Emergent Biosolutions Inc (EBS) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Emergent Biosolutions Inc's capital expenditures?

Emergent Biosolutions Inc (EBS) invested $13.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Emergent Biosolutions Inc spend on research and development?

Emergent Biosolutions Inc (EBS) invested $53.2M in research and development during fiscal year 2025.

Does Emergent Biosolutions Inc buy back shares?

Yes, Emergent Biosolutions Inc (EBS) spent $24.9M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Emergent Biosolutions Inc have outstanding?

Emergent Biosolutions Inc (EBS) had 52M shares outstanding as of fiscal year 2025.

What is Emergent Biosolutions Inc's current ratio?

Emergent Biosolutions Inc (EBS) had a current ratio of 5.01 as of fiscal year 2025, which is generally considered healthy.

What is Emergent Biosolutions Inc's debt-to-equity ratio?

Emergent Biosolutions Inc (EBS) had a debt-to-equity ratio of 1.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Emergent Biosolutions Inc's return on assets (ROA)?

Emergent Biosolutions Inc (EBS) had a return on assets of 4.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Emergent Biosolutions Inc's Altman Z-Score?

Emergent Biosolutions Inc (EBS) has an Altman Z-Score of 1.45, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Emergent Biosolutions Inc's Piotroski F-Score?

Emergent Biosolutions Inc (EBS) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Emergent Biosolutions Inc's earnings high quality?

Emergent Biosolutions Inc (EBS) has an earnings quality ratio of 3.24x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Emergent Biosolutions Inc cover its interest payments?

Emergent Biosolutions Inc (EBS) has an interest coverage ratio of 1.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Emergent Biosolutions Inc?

Emergent Biosolutions Inc (EBS) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.